Magnus Medical

# Magnus Medical: Transforming Depression Treatment Through Personalized Brain Stimulation

High-Level Overview

Magnus Medical is a medical device company developing personalized neuromodulation technology to treat severe depression.[1] The company's flagship product, the SAINT® (Stanford Accelerated Intelligent Neuromodulation Therapy) Neuromodulation System, represents a fundamentally different approach to treating major depressive disorder (MDD)—one that combines advanced brain imaging with artificial intelligence to deliver individualized, rapid-acting therapy.[2]

The company serves adults with treatment-resistant depression who have failed to achieve satisfactory improvement from antidepressant medications.[2] Rather than applying a one-size-fits-all treatment protocol, Magnus Medical uses structural and functional MRI scans to identify each patient's unique brain connectivity patterns, then delivers precisely targeted magnetic stimulation over a five-day treatment window.[1] Clinical data demonstrates that 79% of patients receiving active SAINT treatment experienced relief from severe depression, with approximately 80-90% achieving remission of depression symptoms following the five-day protocol.[3][4]

Origin Story

Magnus Medical was co-founded by Brandon Bentzley, M.D., Ph.D., and Brett Wingeier, Ph.D.[3][4] The company was built on technology originally developed at Stanford University—the SAINT technology was exclusively licensed to Magnus Medical for commercialization.[3][5] This academic-to-commercial transition reflects a deliberate strategy: rather than discovering treatment effects by accident (as has historically occurred with psychiatric medications), Magnus Medical designed SAINT from first principles to address a critical unmet need in mental health care.[7]

The company achieved significant early validation. In October 2021, the FDA granted SAINT the Breakthrough Device Designation, recognizing its potential to provide more effective treatment for a life-threatening or debilitating condition than existing therapies.[3] This was followed by FDA 510(k) clearance in September 2022.[5] Magnus Medical raised $25 million in Series A financing co-led by Jazz Venture Partners and Red Tree Venture Capital,[4] and launched commercially in late 2023 with initial customer sites including the University of Arkansas for Medical Sciences, MUSC Health, and California-based Acacia Clinics and Kaizen Brain Center.[6]

Core Differentiators

Personalized targeting through neuroimaging: Unlike conventional transcranial magnetic stimulation (TMS), which applies stimulation to a standardized anatomical location, SAINT uses a proprietary algorithm informed by each patient's structural and functional MRI scans to identify their optimal stimulation target.[1][5] This precision addresses the underlying neurobiology of depression by targeting the specific brain connectivity patterns associated with each individual's condition.

Rapid treatment timeline: SAINT delivers therapeutic benefit in five days rather than weeks or months, dramatically accelerating access to remission for patients with severe, treatment-resistant depression.[1][6]

Non-invasive delivery: The system uses repetitive magnetic pulses rather than surgical implantation or electrical stimulation, reducing barriers to adoption and patient risk.[2][6]

Clinical evidence: A randomized controlled trial published in the American Journal of Psychiatry demonstrated 79% efficacy in active treatment arms, providing robust validation for the approach.[3]

Biomarker discovery potential: The company's research has identified functional MRI resting-state connectivity as a potential biological signature of major depressive disorder, opening pathways to discover additional biomarkers for other neuropsychiatric conditions.[2]

Role in the Broader Tech Landscape

Magnus Medical operates at the intersection of three powerful trends: the digital transformation of healthcare, the rise of precision medicine, and growing recognition of mental health as a critical public health crisis. Major depressive disorder affects more than 280 million people worldwide and is the leading cause of disability according to the WHO,[5] yet treatment options remain limited and often ineffective—approximately 30% of patients do not respond adequately to antidepressant medications.

The company's approach exemplifies a broader shift toward algorithmic medicine: using advanced imaging, machine learning, and computational biology to move beyond population-level treatment protocols toward individualized therapeutic targeting. This aligns with trends in oncology, cardiology, and neurology, but mental health has historically lagged in adopting such precision approaches. Magnus Medical's FDA Breakthrough Designation and commercial launch signal that regulators and payers are ready to support this evolution in psychiatry.

The timing is particularly favorable. Healthcare systems are increasingly focused on outcomes and cost-effectiveness, and a five-day treatment protocol that achieves 80-90% remission rates presents compelling economics compared to years of medication trials. Additionally, growing acceptance of neuromodulation therapies (evidenced by the expansion of deep brain stimulation and other brain-based treatments) has reduced stigma and regulatory barriers for novel approaches.

Quick Take & Future Outlook

Magnus Medical has positioned itself as a category creator in precision psychiatry. The company's near-term priorities include expanding insurance coverage—it is actively pursuing Medicare reimbursement in hospital outpatient settings and working with private insurers—and scaling manufacturing and clinical capacity to meet demand.[1] Longer-term, the company's research into additional biomarkers suggests potential expansion beyond treatment-resistant depression into other neuropsychiatric disorders, positioning SAINT as a platform technology rather than a single-indication device.

The broader significance lies in demonstrating that mental health treatment can be as precise, rapid, and evidence-based as interventions in other medical specialties. If Magnus Medical successfully scales SAINT and expands its clinical applications, it could catalyze a fundamental reimagining of how psychiatry approaches severe mental illness—moving from trial-and-error medication management to targeted, biomarker-informed neuromodulation. This shift would represent not just a commercial opportunity, but a meaningful advancement in how society treats one of its most pressing health challenges.